Business Context and Reporting Period
This Form 6-K filing by YD Bio Ltd covers the month of August 2025. The report addresses a specific update regarding the Private Placement (PIPE) financing associated with the business combination between YD Bio Limited, Breeze Holdings Acquisition Corp., and YD Biopharma Limited, which was previously disclosed in a Form F-4 Registration Statement declared effective on July 18, 2025.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The only financial figure disclosed is the total commitment amount for the PIPE Financing, which remains at $13.2 million.
Material Changes
A material change occurred in the composition of the PIPE Financing subscribers on August 13, 2025:
- The Company entered into a termination agreement releasing Dr. Keng-Lian Ou, Ph.D., from his subscription obligations.
- Concurrently, the Company entered into a new subscription agreement with Ms. Hsiao Lan Wu.
- Ms. Wu's subscription is for the same amount and on the same terms as Dr. Ou's previous commitment.
- Ms. Wu has no affiliation with the Company or its directors and officers.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of risks and contingencies beyond the administrative update to the financing agreement. No unusual items were reported.
Investor Verification Points
- Confirm the total PIPE Financing commitment remains at $13.2 million despite the subscriber change.
- Verify that the substitution of Ms. Hsiao Lan Wu for Dr. Keng-Lian Ou does not alter the closing timeline or terms of the Business Combination.
- Review the original Form F-4 Registration Statement (File No. 333-283428) for the full context of the business combination and initial financing commitments.